Ferring

Pharma

Saint-Prex, Switzerland · Est. 1950

Ferring is a privately-held Swiss pharmaceutical company focused on specialty pharmaceuticals in reproductive health, gastroenterology, and endocrinology.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

217

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

7 drugs in development

Phase 34

Phase 21

Preclinical4

By Therapeutic Area

top 4

Oncology

330%

Gastroenterology

220%

Psychiatry

110%

Dermatology

110%

R&D Momentum

35/100

Pipeline Velocity

0/100

Trial Completion Rate

84/100

Pipeline Concentration

24/100

Pipeline Freshness

75/100

Strategic Signals

↗Active in Gastroenterology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 31, 2026

Recruiting

A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)

Oct 31, 2026

Recruiting

A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Earlier

Oct 1, 2026TrialProspective, Multi-country, Non-Interventional Study to Investigate REKOVELLE for Ovarian Stimulation: the Effectiveness, Safety, and Patterns Of Use for Asian Women in Real World Practice

Sep 26, 2026TrialProspective, Post-authorisation, Multi-centre, Non-interventional Study to Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

Sep 16, 2026TrialA Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects With Low-grade Upper Tract Urothelial Carcinoma (LG-UTUC)

Sep 5, 2026TrialA Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 12 Months to Less Than 9 Years

Sep 4, 2026TrialREKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey

Sep 3, 2026TrialA Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

4 more events

Aug 29, 2026TrialA Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of FE 999049 for Treatment of Men With Idiopathic Infertility

Feb 25, 2026FDADDAVP — DESMODA

Sep 12, 2025TrialA Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump

Jul 15, 2024TrialAn Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.